Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
Initial data from study expected in first quarter 2023
ENGLEWOOD CLIFFS, NJ, Nov. 21, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue. Initial data from the study is expected during the first quarter of 2023.
Related news for (SILO)
- Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
- Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
- Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
- 24/7 Market News Snapshot 05 June, 2025 – Silo Pharma, Inc. Common Stock (NASDAQ:SILO)
- MoBot alert highlights: NASDAQ: ZENA, NASDAQ: ZJK, NASDAQ: KRON, NASDAQ: SILO, NASDAQ: TGL (06/05/25 08:00 AM)